Key Takeaways for Multiple Myeloma: Treatment Sequencing, Safety, and Patient-Centered Care

The panel concludes by sharing practical takeaways for clinicians managing patients with multiple myeloma. The discussion emphasizes the importance of early treatment planning and referral when considering highly active therapies, particularly CAR T-cell and bispecific antibody approaches. The experts highlight the need for proactive supportive care and careful toxicity management, with infection prevention identified as a key priority as these therapies move into earlier lines of treatment. They also stress that treatment intensity should be individualized, as more therapy is not necessarily better for every patient. Careful consideration of treatment sequencing, duration, toxicity, and patient-specific factors remains essential as the therapeutic landscape continues to evolve. The segment closes with a summary of the program's key themes, including evidence-informed treatment sequencing, treatment duration, safety considerations, and shared decision-making across newly diagnosed and relapsed/refractory multiple myeloma.